marijuana stocks news

Two Rivers Water & Farming Company (TURV)

 

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Total Revenue 1,349   1,072   10   5  
Cost of Revenue 2,208 786
Gross Profit (859) 286   10   5  
Operating Expenses
Research Development
Selling General and Administrative (182) 703 1,005 838
Non Recurring
Others 131 129 124 125
Total Operating Expenses
Operating Income or Loss (808) (546) (1,119) (958)
Income from Continuing Operations
Total Other Income/Expenses Net (32) (99) (71) 11
Earnings Before Interest And Taxes (840) (644) (1,191) (947)
Interest Expense 191 217 307 335
Income Before Tax (1,031) (861) (1,498) (1,282)
Income Tax Expense
Minority Interest 7 4 (5)
Net Income From Continuing Ops (1,132) (857) (1,503) (1,282)
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income (1,024) (857) (1,033) (1,752)
Preferred Stock And Other Adjustments (513) (483) (177) (470)
Net Income Applicable To Common Shares (1,537) (1,340) (1,210) (2,222)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Trulieve Cannabis Corp. (TCNNF) Caps Transformational Year with Record Fourth Quarter and Full Year 2021 Results

Trulieve Caps Transformational Year with Record Fourth Quarter and Full Year 2021…

Tilray, Inc. (TLRY) Strengthens Presence in Latin America with Acquisition of Alef Biotechnology

Tilray® Strengthens Presence in Latin America with Acquisition of Alef Biotechnology Tilray,…

Curaleaf Holdings, Inc. (CURLF) First Quarter 2022 Results

Curaleaf Reports First Quarter 2022 Results Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX:…

AbbVie Inc. (ABBV) and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio

AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio…